Susquehanna International Group, LLP Editas Medicine, Inc. Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

A detailed history of Susquehanna International Group, LLP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 313,197 shares of EDIT stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

313,197

Previous 210,348 48.89%

Holding current value

$1.02 Million

Previous $1.56 Million 6.28%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$4.67 - $7.28 $480,304 - $748,740	102,849 Added 48.89%	313,197 $1.46 Million
Q1 2024 May 07, 2024	BUY	$7.03 - $11.07 $999,138 - $1.57 Million	142,125 Added 208.32%	210,348 $1.56 Million
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $1.74 Million - $3.09 Million	-278,371 Reduced 80.32%	68,223 $691,000
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $540,638 - $727,362	78,127 Added 29.1%	346,594 $2.7 Million
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $89,224 - $160,912	14,029 Added 5.51%	268,467 $2.21 Million
Q1 2023 May 16, 2023	BUY	$7.03 - $11.53 $1 Million - $1.64 Million	142,567 Added 127.44%	254,438 $1.84 Million
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $2.32 Million - $3.68 Million	-278,921 Reduced 71.37%	111,871 $992,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $1.6 Million - $2.56 Million	131,693 Added 50.83%	390,792 $4.78 Million
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $490,409 - $1.05 Million	-49,090 Reduced 15.93%	259,099 $3.07 Million
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $600,385 - $1.18 Million	42,641 Added 16.06%	308,189 $5.86 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $1.29 Million - $1.97 Million	48,447 Added 22.32%	265,548 $7.05 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $4.39 Million - $8.16 Million	-111,909 Reduced 34.01%	217,101 $8.92 Million
Q2 2021 Aug 11, 2021	BUY	$31.29 - $56.64 $4.82 Million - $8.73 Million	154,140 Added 88.15%	329,010 $18.6 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $4.05 Million - $9.23 Million	101,877 Added 139.57%	174,870 $7.35 Million
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $1.71 Million - $5.34 Million	-63,265 Reduced 46.43%	72,993 $5.12 Million
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $2.67 Million - $3.54 Million	-95,321 Reduced 41.16%	136,258 $3.82 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $327,690 - $608,264	17,713 Added 8.28%	231,579 $6.85 Million
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $1.14 Million - $2.52 Million	-76,779 Reduced 26.42%	213,866 $4.24 Million
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $1.9 Million - $3.18 Million	97,398 Added 50.4%	290,645 $8.61 Million
Q3 2019 Nov 14, 2019	SELL	$22.49 - $26.81 $1.74 Million - $2.08 Million	-77,463 Reduced 28.61%	193,247 $4.39 Million
Q2 2019 Aug 16, 2019	BUY	$20.48 - $27.76 $519,577 - $704,271	25,370 Added 10.34%	270,710 $6.7 Million
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $1.42 Million - $1.93 Million	69,409 Added 39.45%	245,340 $6.07 Million
Q1 2019 May 15, 2019	SELL	$19.43 - $26.41 $2.85 Million - $3.87 Million	-146,476 Reduced 45.43%	175,931 $4.3 Million
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $2.83 Million - $4.94 Million	155,358 Added 93.0%	322,407 $7.34 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $528,806 - $734,208	-19,125 Reduced 10.27%	167,049 $5.32 Million
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $1.98 Million - $2.59 Million	63,150 Added 51.33%	186,174 $6.67 Million
Q1 2018 May 15, 2018	SELL	$29.84 - $44.08 $2.8 Million - $4.14 Million	-93,882 Reduced 43.28%	123,024 $4.08 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $4.75 Million - $6.8 Million	216,906	216,906 $6.67 Million

Others Institutions Holding EDIT

# of Institutions

252

Shares Held

58.7M

Call Options Held

494K

Put Options Held

417K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $225M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Editas Medicine, Inc. Transaction History